Roche (RHHBY) announced that the European Medicines Agency, EMA, has approved Vabysmo 6.0 mg single-dose prefilled syringe, ...

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to ...

Roche's Vabysmo® (faricimab) prefilled syringe has received European Medicines Agency approval for treating three major ...

EMA approves Roche’s Vabysmo prefilled syringe for three retinal conditions that can cause blindness: Basel Saturday, December 14, 2024, 10:00 Hrs [IST] Roche announced that the ...

(IN BRIEF) Roche’s Vabysmo® (faricimab) prefilled syringe has received European Medicines Agency approval for treating three major retinal conditions: neovascular age-related macular degeneration ...

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vialsVabysmo has demonstrated rapid and robust vi ...

(RTTNews) - Roche (RHHBY) announced that the European Medicines Agency has approved Vabysmo or faricimab, 6.0 mg single-dose prefilled syringe for use in the treatment of neovascular or 'wet' ...

Optic complications among hospitalized patients with RA, SLE, and SpA were linked to poor outcomes and higher health care costs, especially among Black and Asian patients.

Meaning, you can easily install malware on your phone without realising it. So, what are the signs that you have a virus on your phone? (Picture: Getty) ...

Jefferies Financial Group upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning, Marketbeat.com ...

The EMA has validated Chiesi Global Rare Diseases and Protalix’s submission to update the dosing regimen of pegunigalsidase alfa.

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody ...